Evidence map›Paper›PMID 42098405›Full record

ArticleNpj viruses2026

A broadly-neutralizing antibody against Orthoebolavirus glycoprotein that potentiates the breadth and neutralization of other antibodies.

Francesca R Donnellan, Vamseedhar Rayaprolu, Pramila Rijal, Victoria O'Dowd, Amar Parvate, Heather Callaway, Chitra Hariharan, Dipti Parekh, Sean Hui, Kelly C L Shaffer and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Npj viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Francesca R DonnellanDepartment of Biochemistry, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford, UK.
Vamseedhar RayaproluCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Pramila RijalCAMS Oxford Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, University of Oxford, Oxford, UK.
Victoria O'DowdUCB Pharma, Slough, UK.
Amar ParvateCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Heather CallawayCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Chitra HariharanCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Dipti ParekhCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Sean HuiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Kelly C L ShafferCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Ruben Diaz AvalosCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Lisa SchimanskiMRC Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.
Helena Müller-KräuterInstitute of Virology, Philipps University Marburg, Marburg, Germany.
Thomas StreckerInstitute of Virology, Philipps University Marburg, Marburg, Germany.
Ariane BalaramInfluenza Research Institute, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA.
Peter HalfmannInfluenza Research Institute, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA.
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA.
Daniel J LightwoodUCB Pharma, Slough, UK.
Alain R TownsendCAMS Oxford Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, University of Oxford, Oxford, UK.
Simon J DraperDepartment of Biochemistry, Dorothy Crowfoot Hodgkin Building, University of Oxford, Oxford, UK. simon.draper@paediatrics.ox.ac.uk.

Funding

Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2014 to 2018
$29.6M
Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS) 2018-I2M-2-002Deutsche Forschungsgemeinschaft 197785619/SFB1021Medical Research Council MR/N01796X/1NIAID NIH HHS U19 AI109762NIH HHS U19 AI109762Wellcome TrustWellcome Trust 106917/Z/15/Z
6 · The paper itself

Abstract

Ebolavirus disease (EVD) is caused by multiple species of orthoebolavirus. Monoclonal antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic approved for treatment of EVD caused by Orthoebolavirus zairense (Ebola virus, EBOV). Therefore, mAbs targeting multiple orthoebolavirus species may represent the next generation of EVD therapeutics. Broadly reactive anti-GP mAbs were produced; among these, mAbs 11886 and 11883 were broadly neutralizing in vitro. A 3.0 Å cryo-electron microscopy structure of EBOV GP bound to both mAbs shows that 11886 binds a novel epitope bridging the glycan cap (GC), 3

Identifiers

PMID42098405
PMCPMC13365404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.